AIM: To investigate the safety and effectiveness of semiconductor laser transscleral cyclophotocoagulation(Tscpc)on refractory glaucomatous.

METHODS: A retrospective review of 33 patients(33 eyes)whose eyes were diagnosed as refractory glaucomatous from March 2012 to March 2013 were treated with Tscpc(energy 1 000～3 000mW, time 2 000～3 000ms, range 270°～360°, count 20～40). Ocular symptoms, visual acuity, and intraocular pressure(IOP), ocular protomerite and complications were observed after Tscpc. Patients were followed up 6mo.

RESULTS: The pain sense of 32 patients(97%)disappeared or remarkably relieved at the final follow up. Mean pre-operative IOP was 50.26±9.37mmHg, which was significantly different from the final follow-up 6mo mean IOP 18.38±8.73mmHg(P<0.05). At three month postoperative, IOP of 2 cases(6%)was rise, and those patients were retreated with Tscpc. Complications included inflammation in anterior chamber reaction in 9 cases(27%), hyphema 5 cases(15%), conjunctival hemorrhage 2 cases(6%). Bulbar conjunctival congestion and edema 12 cases(36%), and atrophy of eyeball 1 case(3%).

CONCLUSION: Semiconductor laser transscleral cyclophotocoagulation is a simple, safe and effective method in the treatment of refractory glaucoma.